Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma

Overview

Journal Int J Breast Cancer

Publisher Wiley

Date 2024 Sep 19

PMID 39296928

Authors

Farah Falah Hasan

Mohammed Haider Fadhil

Zainab Khalid Almukhtar

Affiliations

Soon will be listed here.

Abstract

Stromal inflammatory cells in malignant tissue have recently gained increasing interest. Unlike the extensive research on tumor-infiltrating lymphocytes, published data about tumor-infiltrating eosinophils in breast cancer are scarce. Furthermore, similar studies have yet to be conducted in Iraq. : The objective of this study is to examine the presence of eosinophilic infiltration by direct visualization using light microscopy and to analyze its relationship with other histological parameters in a group of Iraqi women diagnosed with invasive mammary cancer. : A retrospective study enrolled 90 histological samples of invasive mammary carcinoma provided by core needle biopsy from a single center, together with their immunohistochemical results for ER and HER2-NEU. Data reviewing, direct morphological visualizations, and counting eosinophilic infiltration in tissue sections were done by two independent pathologists using light microscopy. The results were statistically correlated with the grade, ER, HER2-NEU, calcification, and axillary lymph node status at presentation. : Out of the entire sample size (90), 40 (44%) showed the presence of eosinophilic infiltration in the tissue, both intratumoral and stromal. Further analysis revealed that most eosinophilic infiltrates had an intermediate score (4-19) per 10 consecutive high-power fields. A strong and meaningful statistical relationship was seen between tissue eosinophilic infiltration and HER2/NEU status. A statistically insignificant correlation was seen between tissue eosinophilic infiltration and histological grade, ER receptor status, calcification, and axillary lymph node status at presentation. : Eosinophils are tumor-infiltrating cells in breast cancer, both intratumoral and stromal. The presence of tissue eosinophilic infiltration can predict HER2/NEU negativity in breast cancer.

Citing Articles

Harnessing myeloid cells in cancer.

Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D Mol Cancer. 2025; 24(1):69.

PMID: 40050933 PMC: 11887392. DOI: 10.1186/s12943-025-02249-2.

References

Marichal T, Mesnil C, Bureau F . Homeostatic Eosinophils: Characteristics and Functions. Front Med (Lausanne). 2017; 4:101. PMC: 5504169. DOI: 10.3389/fmed.2017.00101. View

Artham S, Chang C, McDonnell D . Eosinophilia in cancer and its regulation by sex hormones. Trends Endocrinol Metab. 2022; 34(1):5-20. PMC: 10122120. DOI: 10.1016/j.tem.2022.11.002. View

Voorwerk L, Slagter M, Horlings H, Sikorska K, Van de Vijver K, de Maaker M . Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019; 25(6):920-928. DOI: 10.1038/s41591-019-0432-4. View

Meyer J, Alvarez C, Milikowski C, Olson N, Russo I, Russo J . Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005; 18(8):1067-78. DOI: 10.1038/modpathol.3800388. View

Allaoui R, Hagerling C, Desmond E, Warfvinge C, Jirstrom K, Leandersson K . Infiltration of γ⁢δ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer Biomark. 2017; 20(4):395-409. PMC: 5814667. DOI: 10.3233/CBM-170026. View

Amini R, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P . Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer. 2007; 7:165. PMC: 2048965. DOI: 10.1186/1471-2407-7-165. View

Ghebeh H, Elshenawy M, AlSayed A, Al-Tweigeri T . Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer. Immunotherapy. 2022; 14(4):189-199. DOI: 10.2217/imt-2021-0149. View

Blomberg O, Spagnuolo L, Garner H, Voorwerk L, Isaeva O, van Dyk E . IL-5-producing CD4 T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell. 2022; 41(1):106-123.e10. DOI: 10.1016/j.ccell.2022.11.014. View

Kanda A, Yun Y, Bui D, Nguyen L, Kobayashi Y, Suzuki K . The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions. Allergol Int. 2020; 70(1):9-18. DOI: 10.1016/j.alit.2020.11.001. View

10.

Lai W, Xie H, Liu Y, Zheng F, Zhang Y, Lei Q . Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors. Stem Cell Reports. 2021; 16(7):1697-1704. PMC: 8282466. DOI: 10.1016/j.stemcr.2021.06.005. View

11.

Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M . Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother. 2012; 61(9):1527-34. PMC: 11029779. DOI: 10.1007/s00262-012-1288-3. View

12.

Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A . Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014; 15(8):3353-8. DOI: 10.7314/apjcp.2014.15.8.3353. View

13.

Li Z, Wei H, Li S, Wu P, Mao X . The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther. 2022; 16:305-314. PMC: 8801368. DOI: 10.2147/DDDT.S336643. View

14.

Cormier S, Taranova A, Bedient C, Nguyen T, Protheroe C, Pero R . Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006; 79(6):1131-9. PMC: 3496422. DOI: 10.1189/jlb.0106027. View

15.

Poncin A, Onesti C, Josse C, Boulet D, Thiry J, Bours V . Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines. 2021; 9(9). PMC: 8470317. DOI: 10.3390/biomedicines9091087. View

16.

Grisaru-Tal S, Itan M, Grass D, Torres-Roca J, Eschrich S, Gordon Y . Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations. Oncoimmunology. 2021; 10(1):1859732. PMC: 7781846. DOI: 10.1080/2162402X.2020.1859732. View

17.

Niccoli G, Cosentino N . Eosinophils: a new player in coronary atherosclerotic disease. Hypertens Res. 2012; 35(3):269-71. DOI: 10.1038/hr.2011.221. View

18.

Magrone T, Magrone M, Jirillo E . Eosinophils, a Jack of All Trades in Immunity: Therapeutic Approaches for Correcting Their Functional Disorders. Endocr Metab Immune Disord Drug Targets. 2020; 20(8):1166-1181. DOI: 10.2174/1871530320666200309094726. View

19.

Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S . Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021; 22(7):851-864. PMC: 7611091. DOI: 10.1038/s41590-021-00943-z. View

20.

Reichman H, Karo-Atar D, Munitz A . Emerging Roles for Eosinophils in the Tumor Microenvironment. Trends Cancer. 2017; 2(11):664-675. DOI: 10.1016/j.trecan.2016.10.002. View